Literature DB >> 1299669

[Acute chyloperitoneum].

P Michel1, G Pagliano.   

Abstract

A patient presenting with the symptomatology of an appendicular syndrome was later diagnosed as having an acute chylous ascites. The etiology was an acute edematous pancreatitis, the anatomy of the lymphatic pathways with the proximity of the pancreas explaining this etiology, as well as the possibility of a pancreatitis secondary to obstruction of the thoracic duct. The early post-operative clinical course was marked by an acute occlusion of small intestine on the 15th day, related to the adherence potency of the chyle. A general review of the acute chylous ascites syndrome showed the prognosis to be generally favorable, with a mortality of 4%, in contrast to the 40% mortality reported for the chronic chylous ascites of adults.

Entities:  

Mesh:

Year:  1992        PMID: 1299669

Source DB:  PubMed          Journal:  J Chir (Paris)        ISSN: 0021-7697


  5 in total

1.  Chylous ascites. A late complication of massive peripancreatic necrosis.

Authors:  Z Y Zhang; J M Howard
Journal:  Int J Pancreatol       Date:  1997-06

Review 2.  Case report: a rare case of chylous ascites from Mycobacterium avium intracellulare in a patient with AIDS: review of the literature.

Authors:  C Rollhauser; M Borum
Journal:  Dig Dis Sci       Date:  1996-12       Impact factor: 3.199

Review 3.  Chyloperitoneum associated with idiopathic pancreatitis: case report and review of the literature.

Authors:  G D'Amata; M Rega; V Viola; V Bove; P Simeone; G Baiano
Journal:  G Chir       Date:  2016 Jul-Aug

4.  Acute chylous peritonitis due to acute pancreatitis.

Authors:  Georgios K Georgiou; Haralampos Harissis; Michalis Mitsis; Haralampos Batsis; Michalis Fatouros
Journal:  World J Gastroenterol       Date:  2012-04-28       Impact factor: 5.742

5.  Lipoprotein profile of pleural and peritoneal transudates in dogs and cats.

Authors:  Flavio H Alonso; Erica Behling-Kelly; Dori L Borjesson
Journal:  J Vet Intern Med       Date:  2022-02-15       Impact factor: 3.333

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.